TABLE 1.
Demographics and baseline characteristics of patients with CRSwNP with loss‐of‐taste severity score >0 (mild and above, enriched population)
| Pooled SINUS‐24/SINUS‐52 | Placebo (n = 265) | Dupilumab 300 mg q2w (n = 385) | All (n = 650) |
|---|---|---|---|
| Age, mean (SD), years | 51.07 (12.80) | 51.49 (12.98) | 51.32 (12.90) |
| Male sex, n (%) | 152 (57.4) | 236 (61.3) | 388 (59.7) |
| Prior surgery for NP and/or SCS use during previous 2 years, n (%) | 259 (97.7) | 376 (97.7) | 635 (97.7) |
| Prior surgery for NP, n (%) | 174 (65.7) | 238 (61.8) | 412 (63.4) |
| Time since first diagnosis of NP, mean (SD), years | 10.93 (9.02) | 10.81 (9.22) | 10.86 (9.13) |
| Loss‐of‐taste severity score, n (%) | |||
| 1 | 39 (14.7) | 65 (16.9) | 104 (16.0) |
| 2 | 84 (31.7) | 117 (30.4) | 201 (30.9) |
| 3 | 142 (53.6) | 203 (52.7) | 345 (53.1) |
Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; NP, nasal polyps; q2w, every 2 weeks; SCS, systemic corticosteroids; SD, standard deviation.